Isoxicam

Summary

Isoxicam (CHEMBL53292) is an approved small-molecule non-steroidal anti-inflammatory drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 335.34 Da · C14H13N3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL53292
Name	Isoxicam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	54677972
ChEBI	CHEBI:76163
Molecular formula	C14H13N3O5S
Molecular weight	335.34
InChIKey	YYUAYBYLJSNDCX-UHFFFAOYSA-N

SMILES: CC1=CC(=NO1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O

IUPAC name: 4-hydroxy-2-methyl-N-(5-methyl-1,2-oxazol-3-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide

ChEBI definition: A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, antirheumatic drug.

Also known as: Isoxicam, Maxicam, NSC-758436, W 8495, W-8495, isoxicam, SID11112741, SID26747065, SID855966, SID104171326, ISOXICAM, SID170466334

Patent coverage: 4,738 distinct patent families (19,518 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 19,471 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Ubiquitin carboxyl-terminal hydrolase 2, Prelamin-A/C, Vascular endothelial growth factor receptor 2.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.05	Potency	891.3	nM	CHEMBL_ACT_3663833
USP2	5.3	Potency	5012	nM	CHEMBL_ACT_4743918

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).